Kringle Pharma announced that it had entered into a sales licensing and other agreement and raised its earnings forecast for the current fiscal year. Following the announcement, its share price rose to around ¥458 during the morning session, rebounding for the first time in 3 trading days.
Kringle Pharma announced after the market close on the 16th that it had raised its earnings forecast for the current fiscal year. Its shares are being bought at ¥458, up ¥22 from the previous day, in trading during the 9 a.m. hour. They opened higher for the first time in 3 trading days.
The reported signing of the sales licensing and other agreement is cited as the background to the announcement, and there is a view that the market sees the agreement as a factor improving the earnings outlook.
Although the specific figures for the upward revision are not included in the article, the expected improvement in future earnings is being viewed as a positive catalyst. Investors are focusing on the terms of the agreement and the impact of the timing of its realization.